In a first-in-human study of single-dose intravenous delivery of EGFR variant III (EGFRvIII) engineered CAR-T-EGFRvIII cells to 10 recurrent GBM patients, initial reports revealed a safe infusion with no off-tumour toxicity or cytokine release syndrome. Here, EGFR is linked to glioblastoma.